Skip to main content
TERUMO GLOBAL
Select Region
Show — Select Region
Hide — Select Region
Regions/Countries
Japan
United States
Terumo Interventional Systems
Terumo Cardiovascular
Terumo Neuro
Terumo Blood and Cell Technologies
Terumo Aortic
Terumo Medical Products
Terumo Medical Corp
Terumo Health Outcomes
Canada
Europe
Latin America
Latin America
Brazil
Asia Pacific
Australia
Korea
Vietnam
China
India
Global Business website
Terumo Cardiovascular
Terumo Aortic
Terumo Neuro
Terumo Blood and Cell Technologies
Pharmaceutical Solutions
About Terumo
About Terumo
Dear Stakeholders
Group Mission
Who We Are
Corporate Governance
Compliance
Regulations and Standards
Procurement Activity
At a Glance
Leadership Team
History
Brand Video "Our Promise"
Terumo's Response to COVID-19
Education and Training
Terumo Ventures
Business Overview
Business Overview
Terumo Interventional Systems
Terumo Neuro
Terumo Cardiovascular / HeartSheet Division
Terumo Aortic
Hospital Care Solutions
Life Care Solutions
Pharmaceutical Solutions
Terumo Blood and Cell Technologies Company (Terumo Blood and Cell Technologies)
Sustainability
Sustainability
Sustainability News
Sustainability at the Terumo Group
GRI Standards Index
Technology
Technology
From Devices to Solutions
Basic Information
Basic Information Top
Research and Development
Production and Supply
Intellectual Property
Terumo Fellows
Stories - Our Technologies
Investors
Investors
Management Policy
Management Policy
Top Management Message
Business Risks
Disclaimer
IR Policy
Financial Highlights
IR Library
IR Library
Financial Statements
Presentations
Consolidated Financial Statements
Terumo Reports
IR Events
Shareholders & Stock
Shareholders Meeting
Stock Information
Shareholder Return
Credit Ratings and Corporate Bond
Analyst Coverage
Articles of Incorporation
Site Quote
IR Inquiries
News
News
June 27, 2025
Corporate
Terumo Initiates Liquidation Proceedings for Quirem Medical
June 24, 2025
Corporate
Terumo Announces Change of Executive Officers (PDF 75.53 KB)
June 24, 2025
Corporate
Terumo Announces Voting Results for the Election of Directors (PDF 89.95 KB)
Global Network
Global Network
Japan
North America
South America
Europe, Middle East and Africa
Greater China
Asia and Pacific
Menu
Home
Investors
IR Inquiries
IR Inquiries
Top
Notes
Any future replies from Terumo Corporation will be solely addressed to you to answer your message.
Transfer of e-mail replies by Terumo to other parties or use of the replies, in whole or part, without the prior written approval of Terumo Corporation is strictly prohibited.
If we are not able to contact you via e-mail for any reason, we may try to contact you using other communications means.
We may not be able to reply to e-mail encoded in special formats.
We may not reply to the message which is not related to the stock investment issues.
We establish a silent period to prevent the leakage of any material information about the Company’s actual financial performance and to ensure fairness.In principle, the silent period shall begin four weeks prior to the date of the expected announcement of the Company’s actual financial performance and conclude on the date when both the final announcement of financial statements of a fiscal year and the quarterly announcements take place.During this period, we refrain from commenting on its financial performance or answering questions in relation to such performance.
[For more details]
IR Policy
Privacy Policy
IR site
Please assist us by filling in the following fields. This will help us direct your comments.
I'm interested in Terumo Corp. as
individual investor
institutional investor
journalist/news
media
analyst
other
Title
Message
Name
First Name
Last Name
Company
Email
Please fill in the e-mail address again for confirmation
Phone
Fax
Address
City
State/Province
Country
Zip/Postal Code